Psilocybin Research Case Studies: What the Clinical Evidence Shows

Johns Hopkins 2016: Psilocybin for Cancer Anxiety and Depression

The 2016 study by Griffiths et al., published in the Journal of Psychopharmacology, is among the most cited pieces of psilocybin research. It enrolled 51 participants with life-threatening cancer diagnoses and clinically significant depression and/or anxiety. Participants received either a high dose of psilocybin (22–30 mg/70 kg) or an active placebo (niacin) in a cross-over design, with professional support sessions before and after each administration.

Key Findings

• At six months following the high-dose session, approximately 80% of participants showed clinically significant reductions in depression and anxiety scores.
• Around 60% of participants met criteria for a "complete remission" of depression at the six-month follow-up.
• 83% of participants rated the psilocybin experience as among the five most meaningful of their lives; 67% rated it as their single most meaningful experience.
• The magnitude of the "mystical experience" during the session — measured using the Mystical Experience Questionnaire — was the single strongest predictor of therapeutic outcome at follow-up.

A simultaneous study by Grob and colleagues at NYU replicated these findings with a smaller sample, providing converging evidence for the effect.

Imperial College London 2017: Treatment-Resistant Depression

Robin Carhart-Harris and colleagues at Imperial College London published a landmark open-label trial in 2017 examining psilocybin in patients with treatment-resistant depression (TRD) — defined as depression that had failed to respond to at least two adequate antidepressant trials. This population is notoriously difficult to treat and represents a significant unmet clinical need.

Key Findings

• All 20 participants showed measurable reductions in depression scores one week after treatment; this represented a 100% response rate at one week, unprecedented in TRD research.
• At three months, 47% of participants were still in remission — a figure that compares favourably with any existing TRD treatment.
• fMRI neuroimaging conducted before and after treatment revealed significant changes in amygdala reactivity and default mode network (DMN) activity — changes consistent with the hypothesised mechanism by which psilocybin disrupts rigid, self-referential thinking patterns associated with depression.
• As an open-label trial without a placebo control group, these results cannot confirm that psilocybin was the active ingredient — expectation effects may have contributed. The researchers emphasised the need for randomised controlled trials.

A follow-up study by the same group in 2021 directly compared psilocybin with the SSRI escitalopram in a randomised controlled trial of 59 participants. Both treatments produced similar reductions in depression scores on the primary outcome measure, but psilocybin showed advantages on several secondary measures including emotional processing and overall wellbeing.

NYU and Johns Hopkins: Alcohol Use Disorder

Two significant trials have examined psilocybin for alcohol use disorder (AUD), a condition with high mortality and limited effective treatments.

The NYU trial (Bogenschutz et al., 2015, expanded 2022) found that participants receiving psilocybin showed significant reductions in heavy drinking days compared to those receiving an active control. At the 32-week follow-up, 48% of the psilocybin group had abstained from drinking entirely, compared to 24% of the control group. The researchers noted that the strength of the mystical experience during the psilocybin session predicted greater reductions in drinking at follow-up.

A parallel Johns Hopkins trial (Barrett et al., 2022) found similar results, with psilocybin-treated participants showing significantly greater reductions in alcohol craving and consumption compared to the control arm. Participants also reported improved quality of life and reduced depression and anxiety.

COMPASS Pathways Phase IIb Trial

COMPASS Pathways conducted the largest psilocybin clinical trial to date, a Phase IIb randomised controlled trial across 22 sites in 10 countries, published in the New England Journal of Medicine in 2022. This trial enrolled 233 participants with TRD and compared three doses of synthetic psilocybin (1mg, 10mg, and 25mg).

Key Findings

• The 25mg dose produced statistically significant and clinically meaningful reductions in depression scores at three weeks compared to the 1mg control dose.
• 29.1% of participants in the 25mg group showed sustained response at 12 weeks, compared to 9.4% in the 1mg group — a significant difference.
• Adverse events included headache, nausea, dizziness, and fatigue. Serious adverse events were rare; there were no deaths and no cases of psychosis in the trial.
• The trial used a standardised synthetic psilocybin formulation (COMP360) rather than mushrooms, ensuring dose consistency across all sites.

The COMPASS trial demonstrated that psilocybin can produce clinically meaningful antidepressant effects in a large, multisite, rigorous trial design — addressing a key concern about the generalisability of earlier single-site studies.

How to Read Psilocybin Research Critically

As psychedelic research expands, it is important to evaluate studies carefully rather than accepting or dismissing findings wholesale. Key questions to ask when reading any psilocybin study:

• Was there a control condition? Open-label studies (no control group) cannot distinguish drug effects from expectation and placebo effects. Randomised controlled trials are more reliable.
• How was "blinding" handled? It is difficult to blind participants to whether they received psilocybin, because the effects are obvious. Unblinding inflates apparent drug effects in self-reported outcomes.
• What was the sample size? Many psilocybin studies have small samples (20–50 participants). Effects may not replicate at scale, as the COMPASS trial was designed to test.
• What was the setting? All clinical psilocybin research involves significant psychological support before, during, and after sessions. Results cannot be attributed to the drug alone.
• Who funded the study? Industry-funded studies (e.g., COMPASS) may have different publication biases than academic studies funded by NIH or charitable grants.
• What were the adverse events? Even positive studies should report adverse events honestly. Studies that report no adverse events are almost certainly incomplete.

Frequently Asked Questions: Psilocybin Research

What is the most important psilocybin clinical study to date?

Multiple studies are landmark contributions. The 2016 Johns Hopkins cancer anxiety study (Griffiths et al.) established the feasibility and therapeutic potential of psilocybin in a rigorously designed trial. The 2022 COMPASS Pathways Phase IIb trial is the largest psilocybin RCT conducted and provides the most rigorous controlled evidence to date. The Imperial College London 2021 comparison with escitalopram is significant as the first direct comparison of psilocybin with a standard antidepressant. All three are essential reading for understanding the state of evidence.

What is treatment-resistant depression and why is psilocybin being studied for it?

Treatment-resistant depression (TRD) is defined as depression that has not responded adequately to at least two courses of standard antidepressant treatment. Approximately 30% of people with major depressive disorder fall into this category. TRD is associated with high suicide risk, severe impairment, and limited effective options. Psilocybin is being studied for TRD because it appears to produce rapid, large-magnitude antidepressant effects via a different mechanism than conventional treatments — making it potentially effective in people for whom standard treatments have failed.

What is the FDA Breakthrough Therapy designation and has psilocybin received it?

The FDA Breakthrough Therapy designation is granted to drugs that show preliminary clinical evidence of substantial improvement over existing therapies for serious conditions. Psilocybin received Breakthrough Therapy designation from the FDA for treatment-resistant depression in 2018 (COMPASS Pathways) and again in 2019 for major depressive disorder (Usona Institute). This designation expedites the development and review process but does not constitute approval.

Why do clinical psilocybin trials include therapy support alongside the drug?

All clinical psilocybin trials include substantial psychological support — typically several preparation sessions before the drug session and multiple integration sessions afterward. This is not incidental: research evidence suggests that the quality of the therapeutic relationship and the integration support significantly contributes to therapeutic outcomes. Psilocybin works differently from conventional drugs because its mechanism is psychological as well as pharmacological. Studies that isolate the drug from psychological support would likely show weaker effects.

What are the risks identified in clinical trials?

Clinical trials have consistently identified the following risks: nausea and vomiting during onset (common, manageable); transient anxiety and paranoia during the session (common, managed with psychological support); headache following the session (fairly common); transient increases in blood pressure and heart rate during peak effects (relevant for cardiovascular conditions). Serious adverse events are rare in screened clinical populations. No deaths have been recorded in clinical psilocybin trials. The most serious documented risk is psychological distress in people with personal or family histories of psychosis or mania, which is why such individuals are excluded from trials.

How does psilocybin compare to SSRIs for depression?

The 2021 Imperial College London trial directly compared psilocybin with the SSRI escitalopram over six weeks. Both treatments showed similar reductions in depression scores on the primary outcome (QIDS-SR). However, on secondary measures — including emotional blunting, psychological wellbeing, meaning in life, and sexual functioning — psilocybin showed advantages over escitalopram. SSRIs are taken daily and require weeks to show effect; psilocybin's effects appear rapidly following one or two sessions. These are fundamentally different treatment models rather than direct comparisons.

What does the COMPASS Phase IIb trial mean for psilocybin's regulatory future?

The COMPASS Phase IIb trial demonstrated proof of concept in a large, multisite RCT — a requirement for regulatory submissions. COMPASS Pathways announced plans to proceed to Phase III trials based on these results. FDA approval would require successful Phase III trials demonstrating efficacy and safety in larger populations. Most analysts estimate FDA approval for psilocybin in TRD is possible by 2026–2028 if Phase III trials succeed, though regulatory pathways remain complex given psilocybin's Schedule I status.

Are there psilocybin trials for conditions other than depression?

Yes. Active or recently completed psilocybin trials are investigating: alcohol use disorder (NYU, Johns Hopkins), tobacco addiction (Johns Hopkins — a small trial found 80% abstinence at six months, far exceeding standard quit rates), OCD, anorexia nervosa, PTSD, migraine headache, and Alzheimer's disease-related depression. The pipeline is broad, reflecting psilocybin's apparent effects on multiple systems associated with psychiatric conditions.

What is the mystical experience and why does it predict outcomes?

The mystical experience, measured in research using the Mystical Experience Questionnaire (MEQ), is a phenomenological state characterised by: a sense of unity or interconnectedness, sacredness, deeply felt positive mood, transcendence of time and space, ineffability (difficulty putting the experience into words), and paradoxicality. Studies consistently find that higher MEQ scores during a psilocybin session predict stronger therapeutic outcomes months later. Researchers hypothesise that the mystical experience facilitates a shift in self-model and values that underlies therapeutic change.

Where can I read the original research studies?

Key papers are available through: PubMed (pubmed.ncbi.nlm.nih.gov), where most psilocybin clinical trials are indexed; the journal websites of Neuropsychopharmacology, Journal of Psychopharmacology, and New England Journal of Medicine; and through the MAPS Research page (maps.org/research). Many studies are available open-access. Google Scholar searches for "psilocybin depression RCT" or author names (Griffiths, Carhart-Harris, Bogenschutz, Davis) will retrieve most landmark publications.